II. Indications
-
Parkinsonism (adjunctive therapy)
- May reduce "off" time in mid to late Parkinsonism without increasing Dyskinesia
III. Dosing: Parkinsonism
- Start 50 mg orally daily
- May be increased to 100 mg orally daily after 2 weeks
- On discontinuation, taper to 50 mg orally daily for one week before stopping
IV. Metabolism
- Hepatic metabolism
- Avoid in moderate to severe hepatic Impairment
V. Mechanism
- Reversible MAO Inhibitor (Type B)
- Inhibits intracerebral Dopamine metabolism
- Contrast with Rasagiline and Selegiline which irreversibly inhibit MAO B
VI. Adverse Effects
- See MAO Inhibitor
-
Retinopathy
- Based on animal studies
- Periodic Retinal Exams is recommended
-
Skin Discoloration, Hyperbilirubinemia
- Seen in animal studies
VII. Drug Interactions
- See MAO Inhibitors
- Risk of life threatening interactions (Hypertensive Crisis, Serotonin Syndrome)
-
Tyramine Containing Food
- Significant tyramine restriction is not typically needed at typical doses of Type B MAO Inhibitors
- Avoid foods with high tyramine concentrations
VIII. Resources
IX. References
- (2021) Med Lett Drugs Ther 63(1618): 25-32
- Olson (2020) Clinical Pharmacology, Medmaster Miami, p. 46-7
- Hamilton (2020) Tarascon Pocket Pharmacopoeia
Images: Related links to external sites (from Bing)
Related Studies
| xadago (on 7/1/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
| XADAGO 100 MG TABLET | $33.87 each | |